• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

1st recipients of ARVO/Pfizer ophthalmic research awards named

Article

Peng Tee Khaw, MD, and Gholam Peyman, MD, are the first recipients of the ARVO/Pfizer Ophthalmics Translational Research Award. The awards were presented Sunday during the keynote session of the Association for Research in Vision and Ophthalmology (ARVO) annual meeting.

May 2 - Fort Lauderdale, FL - Peng Tee Khaw, MD, and Gholam Peyman, MD, are the first recipients of the ARVO/Pfizer Ophthalmics Translational Research Award. The awards were presented Sunday during the keynote session of the Association for Research in Vision and Ophthalmology (ARVO) annual meeting.

Dr. Khaw, professor of ocular healing and glaucoma at Moorfields Eye Hospital and the Institute of Ophthalmology, University College, London, was recognized for his research in the development of new surgical and medical treatments to prevent scarring after glaucoma and other eye surgeries. Dr. Peyman, professor of ophthalmology at Tulane University, New Orleans, was honored for his translational research leading to the clinical application of numerous ophthalmic developments, including LASIK and photoablative inlay for refractive surgery, eye wall resection, endoresection of intraocular tumors, and his work in intraocular drug delivery.

The ARVO/Pfizer Ophthalmics Translational Research Award, made possible by a grant to the ARVO Foundation from Pfizer Ophthalmics, is presented for excellence in translational research. Translational research is the application of fundamental scientific discoveries and novel technologies to the development and testing of solutions leading to the prevention, treatment, and diagnosis of eye disease.

The recipients received a plaque and $5,000 honorarium.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.